Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05718791 · ClinicalTrials.gov registry record
CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
A clinical trial of GVHD,Acute, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT05718791: Recruiting study of GVHD,Acute, sponsored by Henry Ford Health System.
NCT05718791 is a study of GVHD,Acute that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05718791, a study of GVHD,Acute, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.
Primary Outcome
CXCL9 combined with EASIX can be used as predictors of acute GVHD
Conditions Studied
Interventions
- DIAGNOSTIC_TEST blood sample
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-05-10 |
| Est. Completion | 2026-12-30 |
What NCT05718791 shows while recruiting
NCT05718791 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with GVHD,Acute appearing as the primary indexed condition, and to 1 intervention - of which blood sample is the first listed.
NCT05718791 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05718791 about?
NCT05718791 is a clinical study titled "CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease". The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cel...
What is the current status of trial NCT05718791?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2023-05-10. Estimated completion is 2026-12-30.
What conditions does trial NCT05718791 study?
This clinical trial studies the following conditions: GVHD,Acute.
What interventions are being tested in trial NCT05718791?
The interventions under investigation include: blood sample (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05718791?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05718791 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GVHD,Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI